Ann: Santa drilling highlights growth potential at Mount Belches, page-3

First 3 Last

Share
Profile

Follow
paris123456

1,349 Posts.

8

07/06/18

16:17

Post #: 33570307
Share

Originally posted by MIStragic ↑

Wow - another set of spectacular results which adds to SLR momentum - if SLR continues to add to these, the inferred resources and reserves (bearing in mind this is mainly an underground operation where the strikes are "open at depth") will be very large ensuring long LOM. And if the next quarterly production result is as good or better than the last, then SLR will be a star performer at Diggers&Dealers, and a substantial re-rate must occur. If the POG remains relatively stable, then the SLR SP may crack 100c (?)
As I said in my previous posts, SLR is debt free, a substantial producer with multiple rich long life mines and has substantial cash reserves and hence 'its time' to declare it to the investment world and start paying dividends, like big brother NST did years ago. This would be a confident declaration of independence and would not preclude corporate action, now that SLR shares are no longer the equivalent of toilet paper.
I recently shed 10% of my SLR holding to buy a another chunk of RED5, which like SLR has recently announced some spectacular drill results that indicate how undervalued (like SLR) it is compared to its peers. If the SLR price moves before WAF and CDV recover, I may follow Nordesmic into them as well.

Expand

Market liked the report. I doubled my holdings on earlier trade and sold down RMS by a 1/3.

SLR Price at posting: 58.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals